Classic triad: reduced level of consciousness, respiratory depression (RR <10, especially <8) and pinpoint pupils
Also: hypoxia/cyanosis, bradycardia, hypotension, hypothermia, reduced bowel sounds; needle marks, patches or opioid packaging may be found
Fentanyl and analogues: rapid onset, chest wall rigidity possible. Pupils may not be pinpoint with hypoxia or with tramadol/pethidine; tramadol/pethidine can also cause seizures
Long-acting or modified-release opioids (methadone, buprenorphine, fentanyl, modified-release morphine/oxycodone) can cause prolonged or recurrent toxicity after naloxone wears off
Complications: aspiration, hypoxic brain injury, rhabdomyolysis, non-cardiogenic pulmonary oedema, acute withdrawal after naloxone in dependent patients
Capillary glucose (hypoglycaemia mimic); VBG/ABG if hypoventilating (hypercapnia)
ECG (QT prolongation with methadone; arrhythmias with co-ingestants)
Paracetamol and salicylate levels, and consider co-ingestants (alcohol, benzodiazepines, other sedatives β naloxone will not reverse these)
U&E, creatine kinase if prolonged immobility; CXR if aspiration or pulmonary oedema suspected
Response to naloxone is both diagnostic and therapeutic; if no response after 10 mg total, question the diagnosis. Seek poison-centre/toxicology advice if uncertain
Treatment
Priority β airway and ventilation first: open airway, oxygen, bag-valve-mask ventilation if RR very low or SpO2 low; naloxone is an adjunct, not a replacement for airway support. Start CPR per ALS guidance if in cardiac arrest
Naloxone bolus β acute overdose (opioid-naive/unknown):Naloxone 400 micrograms to 2 mg IV; repeat every 2β3 min until adequate breathing; usual maximum 10 mg β if no response after 10 mg, reconsider the diagnosis. Effect appears within about 2 min IV and lasts roughly 1β4 h
If no IV access:Naloxone IM/SC (same doses) β slower onset but longer effect; intranasal 2β4 mg is an alternative
Low-dose titrated regimen (opioid-dependent, chronic/palliative opioid use, post-operative, or less life-threatening):Naloxone 100β200 micrograms (1.5β3 micrograms/kg) IV, then 100 microgram increments every 2 min until RR >8 and rousable to voice. Aim for adequate breathing rather than full wakefulness to avoid precipitating severe withdrawal
Why an infusion: naloxone acts for a shorter time than many opioids, so relapse into respiratory depression is common. Consider an infusion when repeated doses are needed to keep a good response (RR >8 and at least rousable to voice), or if a long-acting opioid is suspected or known (methadone, buprenorphine, fentanyl, modified-release morphine/oxycodone)
Preparing the infusion:Naloxone 4 mg (10 Γ 400 microgram ampoules) made up to 20 mL with 0.9% sodium chloride = 200 micrograms/mL, via syringe pump
Starting rate: add up the total naloxone given (including pre-hospital doses) that produced a good response, then run 60% of that dose per hour. Table: 400 micrograms β 240 micrograms/h = 1.2 mL/h; 800 β 480 micrograms/h = 2.4 mL/h; 1200 β 720 micrograms/h = 3.6 mL/h; 1400 β 840 micrograms/h = 4.2 mL/h; 1600 β 960 micrograms/h = 4.8 mL/h; 1800 β 1080 micrograms/h = 5.4 mL/h; 2000 β 1200 micrograms/h = 6.0 mL/h
Titrate and monitor: increase or decrease the rate according to response; record pump rate, AVPU and respiratory rate regularly on a chart, with continuous SpO2. If breathing falls again, re-bolus and increase the rate; if agitation/withdrawal or good wakefulness, reduce the rate. Stop when the opioid effect should have worn off
Withdrawal after naloxone: agitation, vomiting, sweating, tachycardia, hypertension, diarrhoea β usually short-lived; prevent by titrating the smallest effective dose, reassure, treat symptomatically; avoid restraint and watch for aspiration
Observation and disposition: monitor for at least 1β2 h after the last naloxone dose for short-acting opioids (local policy applies); observe much longer or admit for long-acting/modified-release opioids, buprenorphine, methadone or an ongoing infusion. Buprenorphine overdose may need higher naloxone doses
Other management: treat co-ingestions and complications (supplemental oxygen, fluids, hypotension, hypothermia, seizures); avoid activated charcoal unless the airway is protected; assess intent and mental health after any intentional overdose; before discharge give overdose-prevention advice, offer take-home naloxone and refer to addiction/mental health services